New Translational Science Hub in Queensland to boost Australia’s biomedical capacity and capability and deliver faster access to mRNA innovations

5 December 2022: Medicines Australia welcomes the new mRNA vaccine hub – the ‘Translational Science Hub’ – to be established in Queensland in an announcement by Sanofi and the Palaszczuk Government today.

Elizabeth de Somer, CEO of Medicines Australia, said the new Hub, once functional, will bring long-term health and economic benefits to Australia.

“The new Translational Science Hub is a $280 million partnership between Sanofi, the Queensland Government, the University of Queensland, and Griffith University.

“Collaboration is key to successful biomedical innovation and a lesson the world has taken from the COVID-19 pandemic.  

“Bringing together the brightest minds from science, health and medicine to create centres of excellence for innovative technologies, here in Australia, will further boost Australia’s contribution to benefit patients and the broader economy.

“Australia has extraordinary talents and potential when it comes to our research and development capabilities. Manufacturing biotherapeutics domestically critically widens our workforce and talent pipelines to the vital areas of medicine and health.

“Today’s announcement demonstrates not only the importance of investing in our domestic capabilities but the importance of investing in medicines and science.

“Congratulations to Sanofi and all the partners for taking bold strides towards a pioneering, international scientific community that focuses on mRNA technology and translational science,” Ms de Somer said.

The Translational Science Hub will be established under an agreement between Sanofi, the University of Queensland, Griffith University and the Queensland Government. For more information, read the Queensland Government announcement and the Sanofi announcement.


For further information or media interviews, please contact:
Chrystianna Moran – 0424 995 118 /